加载中
NASDAQHealthcareBiotechnology
最新数据
US$0.488
−US$0.0373 · -7.10%
Neumora Therapeutics, Inc. is a specialized biopharmaceutical company progressing through clinical trials, dedicated to advancing therapies for a range of neurological, psychiatric, and neurodegenerative conditions. Its most advanced candidate, navacaprant (also known as NMRA-140), is a novel, once-daily oral kappa opioid receptor antagonist currently undergoing Phase 3 clinical trials for the management of major depressive disorder. Additionally, NMRA-511 is in Phase 1 studies, targeting agitation experienced by individuals with Alzheimer's-related dementia. Another compound, NMRA-266, is also in Phase 1 clinical development, aimed at addressing schizophrenia and other related neuropsychiatric conditions. Beyond its clinical programs, Neumora maintains a preclinical pipeline featuring several promising candidates: NMRA-NMDA for schizophrenia, NMRA-CK1d (a CK1d inhibitor initiative) for amyotrophic lateral sclerosis (ALS), NMRA-NLRP3 for specific neurodegenerative ailments, and NMRA-GCase for Parkinson's disease. Tracing its origins to a 2019 incorporation, the company, initially known as RBNC Therapeutics, Inc., adopted its current name, Neumora Therapeutics, Inc., in October 2021. Its corporate headquarters are situated in Watertown, Massachusetts.
常规交易时段
US$0.488
−US$0.0373 · -7.10%
盘中时间采用ET。市场数据可能有所延迟。
Neumora Therapeutics, Inc. is a specialized biopharmaceutical company progressing through clinical trials, dedicated to advancing therapies for a range of neurological, psychiatric, and neurodegenerative conditions. Its most advanced candidate, navacaprant (also known as NMRA-140), is a novel, once-daily oral kappa opioid receptor antagonist currently undergoing Phase 3 clinical trials for the management of major depressive disorder. Additionally, NMRA-511 is in Phase 1 studies, targeting agitation experienced by individuals with Alzheimer's-related dementia. Another compound, NMRA-266, is also in Phase 1 clinical development, aimed at addressing schizophrenia and other related neuropsychiatric conditions. Beyond its clinical programs, Neumora maintains a preclinical pipeline featuring several promising candidates: NMRA-NMDA for schizophrenia, NMRA-CK1d (a CK1d inhibitor initiative) for amyotrophic lateral sclerosis (ALS), NMRA-NLRP3 for specific neurodegenerative ailments, and NMRA-GCase for Parkinson's disease. Tracing its origins to a 2019 incorporation, the company, initially known as RBNC Therapeutics, Inc., adopted its current name, Neumora Therapeutics, Inc., in October 2021. Its corporate headquarters are situated in Watertown, Massachusetts.
日内区间
当前US$0.488
52周区间
当前US$0.488
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
卖出
估值
26
偏贵
情绪
59
多空交织
风险
84
极高风险
动量
24
动能减弱
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Neumora Therapeutics, Inc. is a specialized biopharmaceutical company progressing through clinical trials, dedicated to advancing therapies for a range of neurological, psychiatric, and neurodegenerative conditions. Its most advanced candidate, navacaprant (also known as NMRA-140), is a novel, once-daily oral kappa opioid receptor antagonist currently undergoing Phase 3 clinical trials for the management of major depressive disorder. Additionally, NMRA-511 is in Phase 1 studies, targeting agitation experienced by individuals with Alzheimer's-related dementia. Another compound, NMRA-266, is also in Phase 1 clinical development, aimed at addressing schizophrenia and other related neuropsychiatric conditions. Beyond its clinical programs, Neumora maintains a preclinical pipeline featuring several promising candidates: NMRA-NMDA for schizophrenia, NMRA-CK1d (a CK1d inhibitor initiative) for amyotrophic lateral sclerosis (ALS), NMRA-NLRP3 for specific neurodegenerative ailments, and NMRA-GCase for Parkinson's disease. Tracing its origins to a 2019 incorporation, the company, initially known as RBNC Therapeutics, Inc., adopted its current name, Neumora Therapeutics, Inc., in October 2021. Its corporate headquarters are situated in Watertown, Massachusetts.
日内区间
当前US$0.488
52周区间
当前US$0.488
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 销货成本 | 500万 USD | — | 66.8万 USD | — | — |
| 毛利 | −500万 USD | — | −66.8万 USD | — | — |
| 研究与开发 | 1.76亿 USD | 2.01亿 USD | 1.43亿 USD | 1.05亿 USD | 2.13亿 USD |
| 销售、一般及管理费用 | 6009.1万 USD | 6253.7万 USD | 4480.7万 USD | 3112.1万 USD | 2454.7万 USD |
| 营业费用 | 2.36亿 USD | 2.63亿 USD | 1.88亿 USD | 1.36亿 USD | 2.37亿 USD |
| 利息收入 | 834.4万 USD | 1993.3万 USD | 1661.1万 USD | 456.1万 USD | — |
| 利息支出 | 321.9万 USD | — | — | — | — |
| 折旧和摊销 | 20.8万 USD | 63.1万 USD | 66.8万 USD | 59.4万 USD | 53.8万 USD |
| 营业利润 | −2.41亿 USD | −2.63亿 USD | −1.88亿 USD | −1.36亿 USD | −2.37亿 USD |
| 净利润 | −2.37亿 USD | −2.44亿 USD | −2.36亿 USD | −1.31亿 USD | −2.37亿 USD |
公司数据更新于 2026年10月6日。
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$4.50
上涨空间 822.13%报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI456.93万0.00%2.3万亿 USD0.03%US$383.54+0.77%
Vanguard Extended Market ETFVXF149.77万0.00%954亿 USD0.05%US$238.25+0.46%
iShares Russell 2000 ETFIWM133.03万0.00%790.26亿 USD0.19%US$282.62-0.27%
Vanguard Russell 2000 ETFVTWO78.41万0.00%180亿 USD0.06%US$114.14-0.26%
iShares Russell 2000 Growth ETFIWO55.94万0.00%142.94亿 USD0.24%US$362.12-0.46%
iShares Biotechnology ETFIBB28.91万0.00%105.49亿 USD0.44%US$204.5-1.66%
Schwab U.S. Small-Cap ETFSCHA28.74万0.00%220.83亿 USD0.03%US$33.235-0.02%
Vanguard Health Care ETFVHT26.4万0.00%220亿 USD0.09%US$313.74-0.24%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Russell 2000 ETFIWMVanguard Russell 2000 ETFVTWOiShares Russell 2000 Growth ETFIWOiShares Biotechnology ETFIBBSchwab U.S. Small-Cap ETFSCHAVanguard Health Care ETFVHTAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
